8-K: DURECT Announces Phase 3 Trial Design for Larsucosterol in Alcohol-Associated Hepatitis

DURECT Corporation has finalized the design for its Phase 3 trial of larsucosterol for severe alcohol-associated hepatitis, following a Type B meeting with the FDA under Breakthrough Therapy designation.

Summary

• DURECT Corporation has announced the design of its Phase 3 registrational trial for larsucosterol, a potential treatment for severe alcohol-associated hepatitis (AH).
• The trial design was agreed upon with the FDA following a Type B meeting under the Breakthrough Therapy designation.
• The Phase 3 trial will be a randomized, double-blind, placebo-controlled, multi-center study conducted in the U.S. and will enroll approximately 200 patients.
• The primary endpoint of the trial is 90-day survival, with topline results expected within two years of trial initiation.
• The trial protocol is based on data from the Phase 2b AHFIRM trial, where larsucosterol showed a reduction in 90-day mortality in U.S. patients by 57% and 58% at 30mg and 90mg doses respectively, compared to placebo.
• The FDA has agreed that a single Phase 3 trial will be sufficient for a New Drug Application (NDA), and the Breakthrough Therapy designation allows for a rolling NDA submission.

Sentiment

Score: 8

Explanation: The document is positive due to the progress in the Phase 3 trial design, the Breakthrough Therapy designation, and the promising Phase 2b results. However, the need for funding and the risks associated with clinical trials temper the overall sentiment.

Positives

• The FDA has agreed to the Phase 3 trial design, indicating a positive regulatory pathway.
• The Breakthrough Therapy designation allows for a faster NDA submission process.
• The Phase 2b AHFIRM trial showed significant mortality reduction in U.S. patients treated with larsucosterol.
• The 90-day survival endpoint is considered clinically meaningful and increases the probability of success.
• The company has ongoing discussions with clinical sites and hepatologists to streamline the Phase 3 trial initiation.

Negatives

• The company needs to secure sufficient funding to initiate the Phase 3 trial.
• The numerical improvement in the primary endpoint of mortality or liver transplant at 90 days in the AHFIRM trial did not achieve statistical significance for either dose of larsucosterol.

Risks

• Future clinical trials may not confirm the results from the AHFIRM trial.
• The company may not be able to raise sufficient capital to complete the Phase 3 trial.
• The FDA may require additional clinical trials before approving larsucosterol.
• The Breakthrough Therapy designation may not expedite the approval process.
• There are risks related to the company's cash resources and ability to continue as a going concern.

Future Outlook

The company plans to initiate and enroll patients in the Phase 3 trial in 2024 and expects to present topline data in the second half of 2026, subject to obtaining sufficient funds. They aim to confirm the efficacy and safety of larsucosterol to support an NDA filing with the FDA.

Management Comments

• James E. Brown, D.V.M., President and Chief Executive Officer of DURECT, stated that they are pleased with the collaborative interactions with the FDA.
• James E. Brown believes the primary endpoint of 90-day survival provides the greatest probability of success based on the AHFIRM data.
• Norman Sussman, M.D., FAASLD, Chief Medical Officer of DURECT, stated that there is an urgent need for an effective therapy to reduce the high mortality rate of AH.
• Norman Sussman believes larsucosterol has the potential to save the lives of tens of thousands of patients yearly.

Industry Context

The announcement is significant as there are currently no FDA-approved therapies for alcohol-associated hepatitis, and the high mortality rate underscores the urgent need for effective treatments. DURECT's progress with larsucosterol positions them as a potential leader in this therapeutic area.

Comparison to Industry Standards

• The 90-day mortality rate for AH is approximately 30%, as reported in a global study, highlighting the severity of the condition and the need for effective treatments.
• Current treatments, such as corticosteroids, have limitations and have not shown to improve survival at 90 days or one year.
• Liver transplantation is an option but is limited by organ availability and high costs, exceeding $875,000 per transplant.
• The AHFIRM trial results showing a 57-58% reduction in mortality in U.S. patients with larsucosterol are promising compared to the standard of care.

Stakeholder Impact

• Shareholders may see a positive impact due to the progress of larsucosterol.
• Patients with severe AH may benefit from a new treatment option.
• Clinical sites and investigators will be involved in the Phase 3 trial.
• Employees of DURECT will be involved in the execution of the trial.

Next Steps

• Initiate and enroll patients in the Phase 3 trial of larsucosterol in AH.
• Report topline data from the Phase 3 trial within two years of trial initiation.
• Continue discussions with the FDA under the Breakthrough Therapy designation.
• File a New Drug Application (NDA) as a rolling submission.

Key Dates

Keywords

larsucosterol, alcohol-associated hepatitis, AH, Phase 3 trial, FDA, Breakthrough Therapy, mortality, epigenetic therapy, clinical trial, NDA